Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 85 In PIONEER 1, oral semaglutide demonstrated a superior reduction in HbA1c and body weight at week 26 vs placebo Mean change in HbA1c (%-point) 0.0 Mean change in HbA1c Mean change in body weight (kg) Oral sema 3 mg Oral sema 14 mg Oral sema 7 mg Placebo Mean change in body weight (kg) Oral sema 3 mg Oral sema 14 mg Oral sema 7 mg — Placebo 0.0 -0.4 -0.8 -1.2 -1.6 -2.0 0 Weeks • -0.1 -1.0 -2.0 -0.8* -3.0 •-1.3* •-1.5* -4.0 -5.0 26 261 Weeks 1 Results illustrated by using the secondary statistical method called hypothetical estimand after 26 weeks of treatment: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous semaglutide Statistically significant versus placebo Note: Mean baseline HbA1c: 8.0% sema: semaglutide Source: Presented at the Novo Nordisk investor event at American Diabetes Association, 78th Annual Scientific Sessions, Orlando, FL, USA -1.5 -1.7 -2.5* -4.1* 26 261 novo nordisk

View entire presentation